

GenMark Diagnostics, Inc.  
Form 8-K  
June 20, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2012

**GENMARK DIAGNOSTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34753**  
(Commission  
File Number)

**27-2053069**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: GenMark Diagnostics, Inc. - Form 8-K

**5964 La Place Court, Suite 100**

**Carlsbad, California**  
(Address of principal executive offices)

**760-448-4300**

**92008**  
(Zip Code)

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

GenMark Diagnostics, Inc. (the Company) has prepared presentation materials (the Management Presentation) that management intends to use from time to time on or after June 20, 2012 in presentations about the Company's operations and performance. The Company may use the Management Presentation, possibly with modifications, in presentations to current and potential investors, business partners, customers, employees and others with an interest in the Company and its business.

The information contained in the Management Presentation is summary information that should be considered in the context of the Company's periodic filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Management Presentation speaks as of the date of this Current Report on Form 8-K. While the Company may elect to update the Management Presentation in the future to reflect events and circumstances occurring or existing after the date of this Current Report, the Company specifically disclaims any obligation to do so.

In accordance with General Instruction B.2 of Form 8-K, the Management Presentation is deemed to be furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

99.1 Management Presentation

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENMARK DIAGNOSTICS, INC.**

Date: June 20, 2012

/s/ Matthew R. Cohen  
Matthew R. Cohen  
Senior Vice President, General Counsel and Corporate Secretary